Teva Presents Three-Study AUSTEDO Data Package Reinforcing Long-Term Tardive Dyskinesia Management

Post-approval evidence generation is reshaping how deutetrabenazine fits into tardive dyskinesia (TD) treatment protocols, and Teva Pharmaceuticals used Psych Congress Elevate (June 3–6, Las Vegas) to present a three-study data package that extends the clinical rationale for both AUSTEDO and AUSTEDO XR into earlier and longer treatment windows.

The most operationally relevant dataset for prescribing clinicians comes from the IMPACT-TD Registry, the largest real-world TD study on record. Among patients with mild TD initiating deutetrabenazine, all participants recorded reductions in Abnormal Involuntary Movement Scale (AIMS) scores at three months, with no compromise to psychiatric stability. Participants who reported clinically meaningful baseline burden across activities of daily living, psychosocial functioning, and speech also showed improvement in those domains, a finding that strengthens the evidentiary basis for early intervention.

The RIM-TD open-label study, now at three years, adds a durability dimension that matters for long-term treatment planning. More than 50% of patients achieved a clinically meaningful AIMS response by week 15; a further 23% reached that threshold after week 15, reinforcing that discontinuation before the 15-week mark may foreclose benefit for a substantial patient subset. For QA and medical affairs teams supporting label discussions, the cumulative responder data provides a structured framework for post-marketing commitments and real-world evidence submissions under 21 CFR Part 314 supplemental pathways.

A third analysis examined caregiver education as a diagnostic lever. TD-specific content, developed with patient advocacy groups and distributed via online platforms, prompted 53% of at-risk care recipients to discuss TD with a provider within six months; 34% received a formal diagnosis. The finding has direct implications for health systems working to close the gap between symptom onset and treatment initiation, a gap that post-approval registries like IMPACT-TD are increasingly designed to quantify.

Taken together, the three datasets reflect an industry-wide shift toward structured real-world evidence programs as instruments for label expansion, payer negotiations, and regulatory dialogue, not merely commercial support. For regulatory affairs leads monitoring ICH E1 long-term safety data expectations and FDA's evolving guidance on real-world evidence, Teva's multi-study approach at a single congress represents a model worth tracking.

The next measurable checkpoint is whether the IMPACT-TD mild-TD cohort data surfaces in a supplemental NDA or label update within Teva's disclosed regulatory pipeline timelines.

Source: Teva Pharmaceuticals via GlobeNewswire, June 8, 2026. Data presented at Psych Congress Elevate, June 3–6, 2026, Las Vegas, NV.